Indaptus Therapeutics, Inc. (NASDAQ:INDP) insiders are still down US$35k after purchasing last year, recent gain helped regain some losses

Insiders who bought US$127k worth of Indaptus Therapeutics, Inc. (NASDAQ:INDP) stock in the last year recovered part of their losses as the stock rose by 19% last week. However, total losses seen by insiders are still US$35k since the time of purchase.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for Indaptus Therapeutics

Indaptus Therapeutics Insider Transactions Over The Last Year

Over the last year, we can see that the biggest insider purchase was by CEO & Director Jeffrey Meckler for US$52k worth of shares, at about US$2.63 per share. That means that even when the share price was higher than US$1.81 (the recent price), an insider wanted to purchase shares. It's very possible they regret the purchase, but it's more likely they are bullish about the company. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.

While Indaptus Therapeutics insiders bought shares during the last year, they didn't sell. The chart below shows insider transactions (by companies and individuals) over the last year. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

Indaptus Therapeutics is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Insider Ownership

For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 38% of Indaptus Therapeutics shares, worth about US$5.8m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.

So What Does This Data Suggest About Indaptus Therapeutics Insiders?

It doesn't really mean much that no insider has traded Indaptus Therapeutics shares in the last quarter. However, our analysis of transactions over the last year is heartening. Insiders own shares in Indaptus Therapeutics and we see no evidence to suggest they are worried about the future. While we like knowing what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. For example, Indaptus Therapeutics has 4 warning signs (and 2 which don't sit too well with us) we think you should know about.

Of course Indaptus Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.